Document Detail


Endothelin and its antagonists in hypertension: can we foresee the future?
MedLine Citation:
PMID:  10981045     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Endothelin-receptor antagonists may soon become a new therapeutic class of agents used to treat cardiovascular diseases. Although the first clinical trials are anxiously awaited to position this new family of compounds in the treatment of essential or secondary forms of hypertension, we dispose of an impressive amount of studies in which plasma endothelin levels have been measured, in addition to chronic preclinical studies that provide a general picture of what we can expect from these drugs. The experimental models that do respond to endothelin- receptor antagonists share vascular overexpression of endothelin, which seems directly linked with vascular hypertrophy of resistance arteries. In addition, salt sensitivity may represent an unbalanced condition between relaxing and constrictive properties of the renal endothelium that can respond favorably to endothelin blockade. Thus, African-American hypertensives may well be a responsive target population for the new drugs. In addition to blood pressure control, endothelin may also be involved in the evolution of end-organ damage by its potent vasoactive and vasoproliferative properties. The kidney, heart, large arteries and brain may therefore benefit from these drugs, but it is still unclear if this benefit goes beyond what can be attributed to the reduction of arterial pressure. Moreover, most studies performed so far have looked at prevention of end-organ damage, while very few have addressed the clinically relevant question of regression of lesions already installed by the disease process.
Authors:
P Moreau; T J Rabelink
Related Documents :
10854085 - Clinical pharmacokinetics of angiotensin ii (at1) receptor blockers in hypertension.
17398315 - Systemic hypertension.
12826765 - The economic impact of hypertension.
16625595 - The effects of blood pressure lowering on development of cognitive impairment and demen...
3114445 - Successful four-hour heart-lung preservation with core-cooling on cardiopulmonary bypas...
1333785 - Lower urinary tract function after exstrophy closure.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current hypertension reports     Volume:  1     ISSN:  1522-6417     ISO Abbreviation:  Curr. Hypertens. Rep.     Publication Date:    1999 Feb-Mar
Date Detail:
Created Date:  2001-01-26     Completed Date:  2002-01-02     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100888982     Medline TA:  Curr Hypertens Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  69-78     Citation Subset:  IM    
Affiliation:
Faculty of Pharmacy, Université de Montréal, PO Box 6128, Stn "Centre-ville" Montréal, Québec H3C 3J7, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antihypertensive Agents / adverse effects,  therapeutic use*
Clinical Trials as Topic
Endothelin-1 / physiology*
Humans
Hypertension / drug therapy*,  physiopathology
Receptors, Endothelin / antagonists & inhibitors*,  physiology
Vascular Resistance / drug effects,  physiology
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Endothelin-1; 0/Receptors, Endothelin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Endothelin in heart failure.
Next Document:  Endothelin in cardiovascular control: the role of endothelin antagonists.